Priming of Cultured Neurons with Sabeluzole Results in Long-Lasting Inhibition of Neurotoxin-Induced Tau Expression and Cell Death

Total Page:16

File Type:pdf, Size:1020Kb

Priming of Cultured Neurons with Sabeluzole Results in Long-Lasting Inhibition of Neurotoxin-Induced Tau Expression and Cell Death SYNAPSE 26:95–103 (1997) Priming of Cultured Neurons With Sabeluzole Results in Long-Lasting Inhibition of Neurotoxin-Induced Tau Expression and Cell Death DANIELA UBERTI,1 CLAUDIA RIZZINI,1 PAOLA GALLI,1 MARINA PIZZI,1 MARIAGRAZIA GRILLI,1 ANNE LESAGE,2 PIERFRANCO SPANO,1 AND MAURIZIO MEMO1* 1Division of Pharmacology, Department of Biomedical Sciences and Biotechnologies, School of Medicine, University of Brescia, Brescia, Italy 2Department of Biomemical Pharmacology, Janssen Research Foundation, Beerse, Belgium KEY WORDS cerebellar granule cells; human neuroblastoma SH-SY5Y; glutamate; doxorubicin; Tau proteins; PCR ABSTRACT Sabeluzole was described to have antiischemic, antiepileptic, and cognitive-enhancing properties, and is currently under development for Alzheimer’s disease. Recently, it was reported that repeated treatments with sabeluzole protect cultured rat hippocampal neurons against NMDA- and glutamate-induced neurotoxicity. We evaluated the possibility that sabeluzole elicits neuroprotection by acting, either directly or indirectly, on tau proteins. We found that repeated treatments during development of primary cultures of cerebellar granule cells with nanomolar concentra- tions of sabeluzole resulted in mature cells that were resistant to the excitotoxicity induced by glutamate. Also, sabeluzole treatment specifically prevented the glutamate- induced increase of tau expression without modifying the basal pattern of expression of tau proteins, as shown by measurement of mRNA and protein levels. In human neuroblastoma cell line SH-SY5Y, differentiated by treatment with retinoic acid, doxorubicin increased tau immunoreactivity, and later induced cell death. Both effects were prevented by sabeluzole. Our data indicate that increased tau expression is a common response to different types of cells to neurotoxic agents, and that sabeluzole- induced neuroprotection is functionally associated with the prevention of the injury- mediated increase of tau expression. Synapse 26:95–103, 1997. r 1997 Wiley-Liss, Inc. INTRODUCTION tau proteins are the major component of neurofibrillary Sabeluzole is an experimental drug originally devel- tangles, one of the hallmarks of the Alzheimer’s disease oped for its antiischemic, antiepileptic (Wauquier et al., brain (Braak et al., 1986). We previously found that inhibition of tau expression by tau oligonucleotide 1986), and cognitive-enhancing properties (Clinke and antisense treatment in primary cultures of cerebellar Sahgal, 1986), and it is currently under development granule cells reduced neural vulnerability to glutamate- for Alzheimer’s disease. Recently, it was reported that induced neurotoxicity (Pizzi et al., 1995a). Increased repeated treatments with sabeluzole protect cultured tau expression may thus be considered one of the rat hippocampal neurons against NMDA- and gluta- crucial steps in the chain of intracellular events, in- mate-induced neurotoxicity (Pauwels et al., 1990). How- duced by glutamate, leading to neural death. ever, the site(s) as well as the mechanism(s) of action of In this report we show that increased tau expression sabeluzole responsible for its neuroprotective proper- is a converging effect induced by a variety of neurotoxic ties are up to now largely unknown. agents, and that the neuroprotective properties of We tested the possibility that sabeluzole may elicit sabeluzole, independent of type of experimental injury, neuroprotection by acting, either directly or indirectly, on tau expression. Tau proteins are cytoskeleton- associated, neural proteins promoting microtubule as- *Correspondence to: Prof. Maurizio Memo, Division of Pharmacology, De- sembly and neurite polarization (Caceres and Kosik, partment of Biomedical Sciences and Biotechnologies, School of Medicine, University of Brescia, Via Valsabbina 19, 25123 Brescia, Italy. 1990; Dubrin and Kirschner, 1986). The interest in tau E-mail: [email protected] proteins has recently been increased by the finding that Received 23 May 1996; Accepted 3 October 1996. r 1997 WILEY-LISS, INC. 96 D. UBERTI ET AL. are associated with its capability to prevent such an medium; 24 h later, neurotoxicity was evaluated as increase. percentage of total lactate dehydrogenase (LDH) activ- ity. Extracellular and intracellular LDH activity was MATERIALS AND METHODS measured spectrophotometrically, following NADH- Cell cultures oxidation at 340 nm (Bergmeyer, 1974; Pauwels et al., 1989). Total LDH activity was defined as the sum of Primary cultures of cerebellar granule cells were intracellular and extracellular LDH activity. prepared from 8-day-old Sprague-Dawley rat pups as previously described (Levi et al., 1984). Cells were plated onto poly-1-lysine-coated dishes and cultured in Intracellular calcium concentration basal Eagle’s medium containing 10% heat-inactivated measurement fetal calf serum, 2 mM glutamine, 50 µg/ml gentamicin, Regulation of cytosolic free calcium concentration 5 2 and 25 mM KCl, at a density of 1.5 3 10 cells/cm . was investigated by microfluorimetry in single cerebel- Cytosine arabinoside (100 µM) was added to the cul- lar granule neurons, according to Malgaroli et al. (1987) tures 18 h after seeding to prevent non-neuronal cell with minor modifications (Pizzi et al., 1995a). Briefly, proliferation. Experiments were done after culturing cells were plated onto 100 µg/ml poly-l-lysine-coated the neurons for 12 days in vitro (DIV) unless otherwise glass coverslips and cultured as described above. On indicated. Neuroblastoma cell line SH-SY5Y was rou- DIV 12, cells were loaded with the calcium-sensitive tinely cultured in 1:1 Ham’s F12 Dulbecco’s modified fluorescent dye fura-2, by a 60-min incubation at 37°C Eagle’s medium with 10% fetal calf serum, 2 mM with its acetoxymethyl derivate (4 µM in Krebs-Ringer glutamine, in 120-mm Falcon plastic petri dishes in medium containing 1.3 mg/ml bovine serum albumin, humidified incubators at 37°C with 5% CO . For differ- 2 pH 7.4), and then mounted in a 22-mm holder. Fura-2 entation, cultures were seeded at approximately 105 emission was monitored using an inverted fluorescence cells/dish, and retinoic acid was added to give a final microscope (Nike Diaphot, Ni Ron, Japan) associated concentration of 1025 µM. Medium was changed on with an intensified charge-coupled device camera (Mira- alternate days, and cultures were allowed to differenti- 100 TE; Applied Imaging, Gateshead, UK) which re- ate for at least 3 weeks. corded the 510-nm fluorescence emission in neurons excited through a narrow bandpass filter (340 and 380 Neurotoxicity assay nm). The background was subtracted, and the amount The culture-conditioned media of cerebellar granule of free calcium within the cell bodies was calculated cells were collected, and the cells were washed once from the ratio of 340/380 nm obtained every 3–4 sec. with Locke’s solution (154 mM NaCl, 5.6 mM KCl, 3.6 Calibration was according to external standards of mM NaHCO3, 2.3 mM CaCl2, 5.6 mM glucose, and 5 calcium and fura-2 (Connor, 1986). Fluorescence image mM HEPES, pH 7.4) and exposed to different concentra- acquisition and analysis were performed using the tions of glutamate for 15 min. After this period, cells MIRAcal (Multiple Image Ratioing and Analysis with were washed three times with Locke’s solution contain- Calibration) system by Applied Imaging. ing 1 mM MgSO4 and returned to the original culture- conditioned media. Cells were cultured for an addi- Polymerase chain reaction tional 24 h before intravital staining was performed. To evaluate the acute effect of sabeluzole, 0.001% dimethyl A polymerase chain reaction (PCR)-derived method solfoxide (DMSO) or sabeluzole, prepared from a 100- was used to determinate tau mRNA levels in cerebellar fold concentrated drug solution in 0.1% DMSO, were granule cells (Pizzi et al., 1995b) and in the neuroblas- added 20 min before the glutamate pulse. When the toma SH-SY5Y cell line. Total mRNA was isolated from chronic effect of sabeluzole was investigated, vehicle or the cultures by the method of RNAzol (Chirgwin et al., the drug, prepared as described above, was added to the 1979; Chomczynski and Sacchi, 1987), extracted by cultures on DIV 5 and DIV 8. Cell viability was chloroform-ethanol, and reverse-transcribed with determined by fluorescein diacetate (15 µg/ml) and Moloney murine leukemia virus reverse transcriptase propidium iodite (80 µg/ml) staining as previously in the presence of [32P]dCTP, as recommended by the described (Jones and Senft, 1985). manufacturer (BRL). The resulting cDNA was quanti- Neurotoxicity experiments were also performed on tated by determining the amount of radioactivity incor- differentiated neuroblastoma SH-SY5Y cells. The acute porated into trichloroacetic acid-precipitable nucleic effects of sabeluzole were evaluated by pretreating the acids. PCR was done with Taq polymerase (Perkin- cells with vehicle or the drug 20 min before cell injury, Elmer Cetus) in 100 µl of standard buffer containing 0.5 while chronic effects were studied by adding vehicle or ng cDNA, [32P]dCTP as radioactive tracer, and 1 µM sabeluzole on DIV 14 and DIV 18. On DIV 21, 10 nM specific primers. The following primers were used: doxorubicin, an anthracycline antibiotic that induces 58-AGCCGCCTACAGACTGCCCCTGTG-38, correspond- DNA damage (Cole et al., 1985), was added to the ing to nucleotides 693–717 and referred to as A, and 38- SABELUZOLE INHIBITS CELL DEATH 97 ATTTCTGCTCCATGGTCTGTCTTG-58, corresponding tau, a sequence that appears to be conformationally to nucleotides
Recommended publications
  • (19) 11 Patent Number: 5668117
    US005668117A United States Patent (19) 11 Patent Number: 5,668,117 Shapiro 45 Date of Patent: Sep. 16, 1997 54 METHODS OF TREATING NEUROLOGICAL 4,673,669 6/1987 Yoshikumi et al. ...................... 514.f42 DSEASES AND ETOLOGICALLY RELATED 4,757,054 7/1988 Yoshikumi et al. ... 514742 SYMPTOMOLOGY USING CARBONYL 4,771,075 9/1988 Cavazza ............... ... 514/556 TRAPPNGAGENTS IN COMBINATION 4,801,581 1/1989 Yoshikumi et al. ...................... 514.f42 WITH PREVIOUSLY KNOWN 4,874,750 10/1989 Yoshikumi et al. ...................... 514/42 MEDICAMENTS 4,956,391 9/1990 Sapse .................. 514,810 4,957,906 9/1990 Yoshikumi et al. ...................... 514/25 tor: H . Shani 4,983,586 1/1991 Bodor....................................... 514/58 76 Inventor ES pr.) Price Ave 5,015,570 5/1991 Scangos et al. ............................ 435/6 5,037,851 8/1991 Cavazza ........... ... 514,912 5,252,489 10/1993 Macri ........................................ 436/87 21 Appl. No.: 62,201 5297,562 3/1994 Potter. ... 128/898 al 5,324,667 6/1994 Macri. ... 436/87 22 Filed: Jun. 29, 1993 5,324,668 6/1994 Macri ....................................... 436/87 Related U.S. Application Data I63 Continuation-in-part of set No. 26.617, Feb. 23, 1993, Primary Eminer ohn Kight abandoned, which is a continuation of Ser. No. 660.561, Assistant Examiner-Louise Leary Feb. 22, 1991, abandoned. Attorney, Agent, or Firm-D. J. Perrella (51) Int. Cl. ................... A01N 43/04; A01N 61/00; 57 ABSTRACT C07H1/00; C08B 37/08 52 U.S. C. ................................ 514/55; 514/54; 514/23; Therapeutic compositions comprising an effective amount 514/1: 514/811; 514/866; 514/878; 514/879; of at least one carbonyl trapping agent alone or in combi 514/903; 514/912; 436/518; 436/74; 536/1.11; nation with a therapeutically effective of a co-agent or 536/20 medicament are disclosed.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • A Strategy for Developing New Treatment Paradigms for Neuropsychiatric and Neurocognitive Symptoms in Alzheimer’S Disease
    HYPOTHESIS AND THEORY ARTICLE published: 16 April 2013 doi: 10.3389/fphar.2013.00047 A strategy for developing new treatment paradigms for neuropsychiatric and neurocognitive symptoms in Alzheimer’s disease Hugo Geerts1,2*, Patrick Roberts1,3, Athan Spiros1 and Robert Carr1 1 In Silico Biosciences, Berwyn, PA, USA 2 Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA 3 Oregon Health and Science University, Portland, OR, USA Edited by: Successful disease modifying drug development for Alzheimer’s disease (AD) has hit a David Riddell, Pfizer, USA roadblock with the recent failures of amyloid-based therapies, highlighting the translational Reviewed by: disconnect between preclinical animal models and clinical outcome. Although disease Roland Seifert, Medical School of modifying therapies are the Holy Grail to pursue, symptomatic therapies addressing Hannover, Germany Filippo Caraci, University of Catania, cognitive and neuropsychiatric aspects of the disease are also extremely important for the Italy quality of life of patients and caregivers. Despite the fact that neuropsychiatric problems *Correspondence: in Alzheimer patients are the major driver for costs associated with institutionalization, no Hugo Geerts, In Silico Biosciences, good preclinical animal models with predictive validity have been documented. We propose 686 Westwind Drive, Berwyn, PA a combination of quantitative systems pharmacology (QSP), phenotypic screening and 19312, USA. e-mail: Hugo-Geerts@In-Silico- preclinical animal models as a novel strategy for addressing the bottleneck in both cognitive Biosciences.com and neuropsychiatric drug discovery and development for AD. Preclinical animal models such as transgene rats documenting changes in neurotransmitters with tau and amyloid pathology will provide key information that together with human imaging, pathology and clinical data will inform the virtual patient model.
    [Show full text]
  • Dementia Summary
    Agency for Healthcare Research and Quality Evidence Report/Technology Assessment Number 97 Pharmacological Treatment of Dementia Summary Introduction 1. Does pharmacotherapy for dementia syndromes improve cognitive symptoms and The focus of this review is the pharmacological outcomes? treatment of dementia. Pharmacotherapy is often 2. Does pharmacotherapy delay cognitive the central intervention used to improve deterioration or delay disease onset of symptoms or delay the progression of dementia dementia syndromes? syndromes. The available agents vary with respect 3. Are certain drugs, including alternative to their therapeutic actions, and are supported by medicines (non-pharmaceutical), more varying levels of evidence for efficacy. This report effective than others? is a systematic evaluation of the evidence for 4. Do certain patient populations benefit more pharmacological interventions for the treatment from pharmacotherapy than others? of dementia in the domains of cognition, global 5. What is the evidence base for the treatment function, behavior/mood, quality of life/activities of ischemic vascular dementia (VaD)? of daily living (ADL) and caregiver burden. This review considers different types of Many medications have been studied in dementia populations (not just Alzheimer’s dementia patients. These agents can be classified Disease [AD]) in subjects from both community into three broad categories: and institutional settings. The studies eligible in 1. Cholinergic neurotransmitter modifying this systematic review were restricted to parallel agents, such as acetylcholinesterase inhibitors. RCTs of high methodological quality. 2. Non-cholinergic neurotransmitters/ neuropeptide modifying agents. Methods 3. Other pharmacological agents. A team of content specialists was assembled Although only five agents have been approved from both international and local experts.
    [Show full text]
  • A7471055 Treatment Access Protocol For
    Dacomitinib A7471055 Protocol, 28 January 2015 CLINICAL PROTOCOL — A7471055 TREATMENT ACCESS PROTOCOL FOR PATIENTS PREVIOUSLY TREATED WITH DACOMITINIB ON A CLINICAL TRIAL IN JAPAN Compound: PF-00299804 Compound Name: Dacomitinib United States (US) Investigational New CCI Drug (IND) Number: European Clinical Trials Database N/A (EudraCT) Number: Protocol Number: A7471055 Phase: Phase 2 Page 1 Dacomitinib A7471055 Protocol, 28 January 2015 Document History Document Version Date Summary of Changes Original Protocol 28 January 2015 Not Applicable (N/A) Page 2 Dacomitinib A7471055 Protocol, 28 January 2015 Abbreviations Abbreviation Term AE adverse event ALT alanine transaminase AST aspartate transaminase ATP adenosine triphosphate BUN blood urea nitrogen CRF case report form CSA clinical study agreement CSR clinical study report CTCAE Common Terminology Criteria for Adverse Events DAI dosage and administration instructions DMC data monitoring committee DVT deep vein thrombosis EC ethics committee ECG Electrocardiogram ECOG Eastern Cooperative Group EDP exposure during pregnancy EGFR epidermal growth factor receptor EDTA edetic acid (ethylenediaminetetraacetic acid) GCP Good Clinical Practice HDPE High Density PolyEthylene HER Human Epidermal Growth Factor receptor IB Investigator’s Brochure ICH International Conference on Harmonisation ID Identification IEC institutional ethics committee IND investigational new drug application INR international normalized ratio IRB institutional review board IUD intrauterine device KRAS Kirsten Rat Sarcoma
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Alzheimer Syllabus
    Update on Alzheimer’s Disease June, 2006 Stephen S. Flitman, MD, Medical Director 21 st Century Neurology 3100 North Third Ave Suite 100, Phoenix, Arizona (602) 265-6500 www.neurozone.org Alzheimer’s Disease (AD), first described by Dr. Alois Alzheimer in 1907, is a disorder that 10 million Americans are thought to have, but less than 40% are diagnosed or receiving treatment now. It is very common, affecting people ages 40-90 with 2-4% prevalence at ages 65- 75 and increasing in subsequent decades. After heart disease, cancer, and stroke it is the fourth leading cause of death in the US. AD is a disorder of the gray matter of the cerebral cortex. It is characterized clinically by gradually progressive dementia and pathologically by extraneuronal plaques and intraneuronal neurofibrillary tangles by light microscopy. AD progresses anatomically via the connections made by affected neurons. It starts in the entorhinal cortex and then spreads to the hippocampus, basal nuclei, and then to the neocortex. It spares primary motor and sensory cortices, preferentially attacking association areas in the frontal, parietal, and temporal lobes. Affected regions have neurochemical deficits of acetylcholine, glutamate, and serotonin. The degree of dementia correlates with the decline in these neurotransmitters in biopsy or autopsy tissue. While short-term memory deficits predominate early in the progressive dementias, the term dementia is reserved for a clinical syndrome of memory disorder plus at least one other cognitive realm: language, motor or procedural memory (praxis), spatial function, and executive function (decision-making, planning, overall control of behavior). As an etiology for dementia, AD accounts for about two-thirds of cases, with metabolic causes and Lewy body disease making up the lion’s share of the remaining third.
    [Show full text]
  • Sigma, PCP, and NMDA Receptors
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Sigma, PCP, and NMDA Receptors 133 U.S. Department of Health and Human Services • Public Health Service • National Institutes of Health Sigma, PCP, and NMDA Receptors Editors: Errol B. De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse Doris Clouet, Ph.D. Division of Basic Research National Institute on Drug Abuse Edythe D. London, Ph.D. Addiction Research Center National Institute on Drug Abuse Research Monograph 133 1993 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Substance Abuse and Mental Health Services Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGMENT This monograph is based on the papers and discussions from a technical review on “Sigma, PCP, and NMDA Receptors Systems” held on September 27-28, 1989, in Baltimore, MD. The review meeting was sponsored by the National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the Department of Health and Human Services.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0184806 A1 Barlow Et Al
    US 20100184806A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0184806 A1 Barlow et al. (43) Pub. Date: Jul. 22, 2010 (54) MODULATION OF NEUROGENESIS BY PPAR (60) Provisional application No. 60/826,206, filed on Sep. AGENTS 19, 2006. (75) Inventors: Carrolee Barlow, Del Mar, CA (US); Todd Carter, San Diego, CA Publication Classification (US); Andrew Morse, San Diego, (51) Int. Cl. CA (US); Kai Treuner, San Diego, A6II 3/4433 (2006.01) CA (US); Kym Lorrain, San A6II 3/4439 (2006.01) Diego, CA (US) A6IP 25/00 (2006.01) A6IP 25/28 (2006.01) Correspondence Address: A6IP 25/18 (2006.01) SUGHRUE MION, PLLC A6IP 25/22 (2006.01) 2100 PENNSYLVANIA AVENUE, N.W., SUITE 8OO (52) U.S. Cl. ......................................... 514/337; 514/342 WASHINGTON, DC 20037 (US) (57) ABSTRACT (73) Assignee: BrainCells, Inc., San Diego, CA (US) The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system (21) Appl. No.: 12/690,915 including by stimulating or increasing neurogenesis, neuro proliferation, and/or neurodifferentiation. The disclosure (22) Filed: Jan. 20, 2010 includes compositions and methods based on use of a peroxi some proliferator-activated receptor (PPAR) agent, option Related U.S. Application Data ally in combination with one or more neurogenic agents, to (63) Continuation-in-part of application No. 1 1/857,221, stimulate or increase a neurogenic response and/or to treat a filed on Sep. 18, 2007. nervous system disease or disorder. Patent Application Publication Jul. 22, 2010 Sheet 1 of 9 US 2010/O184806 A1 Figure 1: Human Neurogenesis Assay Ciprofibrate Neuronal Differentiation (TUJ1) 100 8090 Ciprofibrates 10-8.5 10-8.0 10-7.5 10-7.0 10-6.5 10-6.0 10-5.5 10-5.0 10-4.5 Conc(M) Patent Application Publication Jul.
    [Show full text]
  • Phenoconversion of Cytochrome P450 Metabolism: a Systematic Review
    Journal of Clinical Medicine Review Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review Sylvia D. Klomp 1,2 , Martijn L. Manson 2,3 , Henk-Jan Guchelaar 1,2 and Jesse J. Swen 1,2,* 1 Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; [email protected] (S.D.K.); [email protected] (H.-J.G.) 2 Leiden Network for Personalised Therapeutics, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; [email protected] 3 Division of BioTherapeutics, Leiden Academic Centre for Drug Research (LACDR), Leiden University, 2333 CC Leiden, The Netherlands * Correspondence: [email protected] Received: 3 August 2020; Accepted: 4 September 2020; Published: 7 September 2020 Abstract: Phenoconversion is the mismatch between the individual’s genotype-based prediction of drug metabolism and the true capacity to metabolize drugs due to nongenetic factors. While the concept of phenoconversion has been described in narrative reviews, no systematic review is available. A systematic review was conducted to investigate factors contributing to phenoconversion and the impact on cytochrome P450 metabolism. Twenty-seven studies met the inclusion criteria and were incorporated in this review, of which 14 demonstrate phenoconversion for a specific genotype group. Phenoconversion into a lower metabolizer phenotype was reported for concomitant use of CYP450-inhibiting drugs, increasing age, cancer, and inflammation. Phenoconversion into a higher metabolizer phenotype was reported for concomitant use of CYP450 inducers and smoking. Moreover, alcohol, pregnancy, and vitamin D exposure are factors where study data suggested phenoconversion. The studies reported genotype–phenotype discrepancies, but the impact of phenoconversion on the effectiveness and toxicity in the clinical setting remains unclear.
    [Show full text]
  • Florencio Zaragoza Dörwald Lead Optimization for Medicinal Chemists
    Florencio Zaragoza Dorwald¨ Lead Optimization for Medicinal Chemists Related Titles Smith, D. A., Allerton, C., Kalgutkar, A. S., Curry, S. H., Whelpton, R. van de Waterbeemd, H., Walker, D. K. Drug Disposition and Pharmacokinetics and Metabolism Pharmacokinetics in Drug Design From Principles to Applications 2012 2011 ISBN: 978-3-527-32954-0 ISBN: 978-0-470-68446-7 Gad, S. C. (ed.) Rankovic, Z., Morphy, R. Development of Therapeutic Lead Generation Approaches Agents Handbook in Drug Discovery 2012 2010 ISBN: 978-0-471-21385-7 ISBN: 978-0-470-25761-6 Tsaioun, K., Kates, S. A. (eds.) Han, C., Davis, C. B., Wang, B. (eds.) ADMET for Medicinal Chemists Evaluation of Drug Candidates A Practical Guide for Preclinical Development 2011 Pharmacokinetics, Metabolism, ISBN: 978-0-470-48407-4 Pharmaceutics, and Toxicology 2010 ISBN: 978-0-470-04491-9 Sotriffer, C. (ed.) Virtual Screening Principles, Challenges, and Practical Faller, B., Urban, L. (eds.) Guidelines Hit and Lead Profiling 2011 Identification and Optimization ISBN: 978-3-527-32636-5 of Drug-like Molecules 2009 ISBN: 978-3-527-32331-9 Florencio Zaragoza Dorwald¨ Lead Optimization for Medicinal Chemists Pharmacokinetic Properties of Functional Groups and Organic Compounds The Author All books published by Wiley-VCH are carefully produced. Nevertheless, authors, Dr. Florencio Zaragoza D¨orwald editors, and publisher do not warrant the Lonza AG information contained in these books, Rottenstrasse 6 including this book, to be free of errors. 3930 Visp Readers are advised to keep in mind that Switzerland statements, data, illustrations, procedural details or other items may inadvertently be Cover illustration: inaccurate.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,746,678 B1 Shapiro (45) Date of Patent: *Jun
    USOO6746678B1 (12) United States Patent (10) Patent No.: US 6,746,678 B1 Shapiro (45) Date of Patent: *Jun. 8, 2004 (54) METHOD OF TREATING NEUROLOGICAL 5,358,720 A * 10/1994 Koppel et al. .............. 424/639 DISEASES AND ETIOLOGICALLY RELATED 5,405,613 A 4/1995 Rowland .................... 424/439 SYMPTOMOLOGY USING CARBONYL 5,532,275 A 7/1996 Grumet ...................... 514/567 TRAPPING AGENTS IN COMBINATION 5,668,117 A * 9/1997 Shapiro ....................... 514/55 WITH MEDCAMENTS OTHER PUBLICATIONS (76) Inventor: Howard K. Shapiro, 214 Price Ave., Apt. F-32, Narberth, PA (US) 19072 52" eddition, Physician Desk Reference, 1998, p. 1184.* (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 * cited by examiner U.S.C. 154(b) by 0 days. Primary Examiner Thurman K. Page This patent is Subject to a terminal dis- Assistant Examiner Blessing Fubara CC. (57) ABSTRACT (21) Appl. No.: 09/545,870 This invention defines a novel method for treatment of (22) Filed: Apr. 6, 2000 Several neurological diseases and pathophysiologically O O related Symptomology, Said diseases including peripheral Related U.S. Application Data neuropathies, Secondary Symptomology of diabetes, Alzhe (63) Continuation-in-part of application No. 08/883,290, filed on s' S s Parkinson's d aSC, albeit polyropa Jun. 26, 1997, now abandoned, which is a continuation-in- thy an age-onset Symptomology, as well as analogous part of application No. 08/062,201, filed on Jun. 29, 1993, Veterinary disease States. An opportunity exists for pharma now Pat No. 5.668,117, which is a continuation-in-part of cological intervention in Some neurological diseases by use E.
    [Show full text]